Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM-101 in sickle cell disease with severe vaso-occlusive crises
NCT05456880Phase 2Active, not recruiting
- Sponsor
- Beam Therapeutics
- Start
- Aug 2022
- Primary completion
- Feb 2028
- Modality
- Gene Silencing, CRISPR-Cas9, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of BEAM-101 in sickle cell disease (SCD), sponsored by Beam Therapeutics. Started Aug 2022; status: active, not recruiting.
02
Drugs
BEAM-101
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05456880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456880.